JP2009536926A - 抗真菌剤を含む複合製剤の使用 - Google Patents
抗真菌剤を含む複合製剤の使用 Download PDFInfo
- Publication number
- JP2009536926A JP2009536926A JP2009508042A JP2009508042A JP2009536926A JP 2009536926 A JP2009536926 A JP 2009536926A JP 2009508042 A JP2009508042 A JP 2009508042A JP 2009508042 A JP2009508042 A JP 2009508042A JP 2009536926 A JP2009536926 A JP 2009536926A
- Authority
- JP
- Japan
- Prior art keywords
- treatment
- candidiasis
- vaginal
- adhesion
- clotrimazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940121375 antifungal agent Drugs 0.000 title claims description 35
- 239000003429 antifungal agent Substances 0.000 title claims description 29
- 238000002360 preparation method Methods 0.000 title description 17
- 238000011282 treatment Methods 0.000 claims abstract description 82
- 210000002889 endothelial cell Anatomy 0.000 claims abstract description 31
- 210000002919 epithelial cell Anatomy 0.000 claims abstract description 28
- 239000003112 inhibitor Substances 0.000 claims abstract description 23
- 241000222122 Candida albicans Species 0.000 claims abstract description 18
- 201000004624 Dermatitis Diseases 0.000 claims abstract description 18
- 230000021164 cell adhesion Effects 0.000 claims abstract description 18
- 206010007134 Candida infections Diseases 0.000 claims abstract description 16
- 201000003984 candidiasis Diseases 0.000 claims abstract description 16
- 230000000699 topical effect Effects 0.000 claims abstract description 15
- 229940079593 drug Drugs 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 14
- 208000007027 Oral Candidiasis Diseases 0.000 claims abstract description 13
- 208000010668 atopic eczema Diseases 0.000 claims abstract description 11
- 206010050346 Oropharyngeal candidiasis Diseases 0.000 claims abstract description 9
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 claims abstract description 6
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims description 28
- 229960004022 clotrimazole Drugs 0.000 claims description 27
- 239000000126 substance Substances 0.000 claims description 26
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 18
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 18
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 claims description 15
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims description 14
- 239000002674 ointment Substances 0.000 claims description 11
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 claims description 10
- -1 capsofundine Chemical compound 0.000 claims description 10
- 229960004884 fluconazole Drugs 0.000 claims description 10
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 claims description 10
- 230000005764 inhibitory process Effects 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 229960002509 miconazole Drugs 0.000 claims description 9
- 239000006071 cream Substances 0.000 claims description 8
- 229960001259 diclofenac Drugs 0.000 claims description 8
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 8
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- 229960001123 epoprostenol Drugs 0.000 claims description 7
- 229960001680 ibuprofen Drugs 0.000 claims description 7
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 6
- 229960003464 mefenamic acid Drugs 0.000 claims description 6
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 claims description 6
- 229960000988 nystatin Drugs 0.000 claims description 5
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 claims description 5
- 230000003511 endothelial effect Effects 0.000 claims description 4
- 229960002202 lornoxicam Drugs 0.000 claims description 4
- OXROWJKCGCOJDO-JLHYYAGUSA-N lornoxicam Chemical compound O=C1C=2SC(Cl)=CC=2S(=O)(=O)N(C)\C1=C(\O)NC1=CC=CC=N1 OXROWJKCGCOJDO-JLHYYAGUSA-N 0.000 claims description 4
- 239000000003 vaginal tablet Substances 0.000 claims description 4
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 229960004369 flufenamic acid Drugs 0.000 claims description 3
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 claims description 3
- 229960000905 indomethacin Drugs 0.000 claims description 3
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims description 3
- 229960000991 ketoprofen Drugs 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 150000003815 prostacyclins Chemical class 0.000 claims description 3
- 239000006216 vaginal suppository Substances 0.000 claims description 3
- 229940044977 vaginal tablet Drugs 0.000 claims description 3
- MPIPASJGOJYODL-SFHVURJKSA-N (R)-isoconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@@H](OCC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 MPIPASJGOJYODL-SFHVURJKSA-N 0.000 claims description 2
- ZCJYUTQZBAIHBS-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-{[4-(phenylsulfanyl)benzyl]oxy}ethyl]imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C=CC(SC=2C=CC=CC=2)=CC=1)CN1C=NC=C1 ZCJYUTQZBAIHBS-UHFFFAOYSA-N 0.000 claims description 2
- OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 claims description 2
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 claims description 2
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims description 2
- XILVEPYQJIOVNB-UHFFFAOYSA-N 2-[3-(trifluoromethyl)anilino]benzoic acid 2-(2-hydroxyethoxy)ethyl ester Chemical compound OCCOCCOC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 XILVEPYQJIOVNB-UHFFFAOYSA-N 0.000 claims description 2
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 claims description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 2
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 claims description 2
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 2
- 229960003942 amphotericin b Drugs 0.000 claims description 2
- 229960002206 bifonazole Drugs 0.000 claims description 2
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 claims description 2
- 239000007936 buccal or sublingual tablet Substances 0.000 claims description 2
- 229960000962 bufexamac Drugs 0.000 claims description 2
- MXJWRABVEGLYDG-UHFFFAOYSA-N bufexamac Chemical compound CCCCOC1=CC=C(CC(=O)NO)C=C1 MXJWRABVEGLYDG-UHFFFAOYSA-N 0.000 claims description 2
- 229960002962 butenafine Drugs 0.000 claims description 2
- ABJKWBDEJIDSJZ-UHFFFAOYSA-N butenafine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)CC1=CC=C(C(C)(C)C)C=C1 ABJKWBDEJIDSJZ-UHFFFAOYSA-N 0.000 claims description 2
- 229960003009 clopidogrel Drugs 0.000 claims description 2
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims description 2
- 229960003913 econazole Drugs 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 229960001493 etofenamate Drugs 0.000 claims description 2
- 229960000192 felbinac Drugs 0.000 claims description 2
- 229960001274 fenticonazole Drugs 0.000 claims description 2
- 229960004413 flucytosine Drugs 0.000 claims description 2
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 229960004849 isoconazole Drugs 0.000 claims description 2
- 229960004130 itraconazole Drugs 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 229960003255 natamycin Drugs 0.000 claims description 2
- 235000010298 natamycin Nutrition 0.000 claims description 2
- 239000004311 natamycin Substances 0.000 claims description 2
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 claims description 2
- 229960004031 omoconazole Drugs 0.000 claims description 2
- JMFOSJNGKJCTMJ-ZHZULCJRSA-N omoconazole Chemical compound C1=CN=CN1C(/C)=C(C=1C(=CC(Cl)=CC=1)Cl)\OCCOC1=CC=C(Cl)C=C1 JMFOSJNGKJCTMJ-ZHZULCJRSA-N 0.000 claims description 2
- 229960003483 oxiconazole Drugs 0.000 claims description 2
- QRJJEGAJXVEBNE-MOHJPFBDSA-N oxiconazole Chemical compound ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)\CN1C=NC=C1 QRJJEGAJXVEBNE-MOHJPFBDSA-N 0.000 claims description 2
- 229960002702 piroxicam Drugs 0.000 claims description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 229960002871 tenoxicam Drugs 0.000 claims description 2
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 claims description 2
- 229960002722 terbinafine Drugs 0.000 claims description 2
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 claims description 2
- 229960005001 ticlopidine Drugs 0.000 claims description 2
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 claims description 2
- 229940098465 tincture Drugs 0.000 claims description 2
- 229940044953 vaginal ring Drugs 0.000 claims description 2
- 239000006213 vaginal ring Substances 0.000 claims description 2
- 229940120293 vaginal suppository Drugs 0.000 claims description 2
- 101000919849 Homo sapiens Cytochrome c oxidase subunit 1 Proteins 0.000 claims 2
- 101000605122 Homo sapiens Prostaglandin G/H synthase 1 Proteins 0.000 claims 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims 1
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical group NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 claims 1
- 101000725401 Homo sapiens Cytochrome c oxidase subunit 2 Proteins 0.000 claims 1
- 101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 claims 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims 1
- 108010017796 epoxidase Proteins 0.000 claims 1
- 230000007717 exclusion Effects 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 150000004291 polyenes Chemical class 0.000 claims 1
- 229940031439 squalene Drugs 0.000 claims 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims 1
- 244000052769 pathogen Species 0.000 description 24
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 22
- 206010017533 Fungal infection Diseases 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 18
- 201000010099 disease Diseases 0.000 description 17
- 208000024386 fungal infectious disease Diseases 0.000 description 16
- 230000009471 action Effects 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 230000001717 pathogenic effect Effects 0.000 description 15
- 230000002538 fungal effect Effects 0.000 description 14
- 210000003491 skin Anatomy 0.000 description 14
- 230000009885 systemic effect Effects 0.000 description 14
- 108010037464 Cyclooxygenase 1 Proteins 0.000 description 13
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 13
- 210000004877 mucosa Anatomy 0.000 description 12
- 206010046914 Vaginal infection Diseases 0.000 description 11
- 201000008100 Vaginitis Diseases 0.000 description 11
- 230000007246 mechanism Effects 0.000 description 11
- 210000003905 vulva Anatomy 0.000 description 11
- 229940114079 arachidonic acid Drugs 0.000 description 10
- 235000021342 arachidonic acid Nutrition 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 238000009097 single-agent therapy Methods 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 230000000843 anti-fungal effect Effects 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 8
- 239000013543 active substance Substances 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 229940111134 coxibs Drugs 0.000 description 7
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 230000035935 pregnancy Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 208000010484 vulvovaginitis Diseases 0.000 description 7
- 238000012404 In vitro experiment Methods 0.000 description 6
- 208000031888 Mycoses Diseases 0.000 description 6
- 210000003756 cervix mucus Anatomy 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 150000003180 prostaglandins Chemical class 0.000 description 6
- 210000001215 vagina Anatomy 0.000 description 6
- 241000233866 Fungi Species 0.000 description 5
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 5
- 206010046901 vaginal discharge Diseases 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000008034 disappearance Effects 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 241001313288 Labia Species 0.000 description 3
- 208000003351 Melanosis Diseases 0.000 description 3
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 3
- 208000037273 Pathologic Processes Diseases 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 229940000425 combination drug Drugs 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 210000003038 endothelium Anatomy 0.000 description 3
- 229940083666 fluconazole 150 mg Drugs 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000011221 initial treatment Methods 0.000 description 3
- 238000011866 long-term treatment Methods 0.000 description 3
- 229960001929 meloxicam Drugs 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 3
- 230000009054 pathological process Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000006461 physiological response Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 108010047303 von Willebrand Factor Proteins 0.000 description 3
- 102100036537 von Willebrand factor Human genes 0.000 description 3
- 229960001134 von willebrand factor Drugs 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 102100037362 Fibronectin Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 2
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- 102100035140 Vitronectin Human genes 0.000 description 2
- 108010031318 Vitronectin Proteins 0.000 description 2
- 206010064899 Vulvovaginal mycotic infection Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 230000025845 adhesion to host Effects 0.000 description 2
- 229960005142 alclofenac Drugs 0.000 description 2
- ARHWPKZXBHOEEE-UHFFFAOYSA-N alclofenac Chemical compound OC(=O)CC1=CC=C(OCC=C)C(Cl)=C1 ARHWPKZXBHOEEE-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- CNBGNNVCVSKAQZ-UHFFFAOYSA-N benzydamine Chemical compound C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 CNBGNNVCVSKAQZ-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 231100000749 chronicity Toxicity 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 229960005293 etodolac Drugs 0.000 description 2
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 229950006236 fenclofenac Drugs 0.000 description 2
- IDKAXRLETRCXKS-UHFFFAOYSA-N fenclofenac Chemical compound OC(=O)CC1=CC=CC=C1OC1=CC=C(Cl)C=C1Cl IDKAXRLETRCXKS-UHFFFAOYSA-N 0.000 description 2
- 229960002390 flurbiprofen Drugs 0.000 description 2
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 2
- 230000007124 immune defense Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 229960004752 ketorolac Drugs 0.000 description 2
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 229960003768 lonazolac Drugs 0.000 description 2
- XVUQHFRQHBLHQD-UHFFFAOYSA-N lonazolac Chemical compound OC(=O)CC1=CN(C=2C=CC=CC=2)N=C1C1=CC=C(Cl)C=C1 XVUQHFRQHBLHQD-UHFFFAOYSA-N 0.000 description 2
- 229960003803 meclofenamic acid Drugs 0.000 description 2
- 239000012907 medicinal substance Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 229960004270 nabumetone Drugs 0.000 description 2
- 229960002009 naproxen Drugs 0.000 description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
- 229960000965 nimesulide Drugs 0.000 description 2
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 2
- 244000039328 opportunistic pathogen Species 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- AFNXATANNDIXLG-SFHVURJKSA-N 1-[(2r)-2-[(4-chlorophenyl)methylsulfanyl]-2-(2,4-dichlorophenyl)ethyl]imidazole Chemical compound C1=CC(Cl)=CC=C1CS[C@H](C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 AFNXATANNDIXLG-SFHVURJKSA-N 0.000 description 1
- JLGKQTAYUIMGRK-UHFFFAOYSA-N 1-{2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C2=CC=CC(Cl)=C2SC=1)CN1C=NC=C1 JLGKQTAYUIMGRK-UHFFFAOYSA-N 0.000 description 1
- TYCOFFBAZNSQOJ-UHFFFAOYSA-N 2-[4-(3-fluorophenyl)phenyl]propanoic acid Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC(F)=C1 TYCOFFBAZNSQOJ-UHFFFAOYSA-N 0.000 description 1
- XKSAJZSJKURQRX-UHFFFAOYSA-N 2-acetyloxy-5-(4-fluorophenyl)benzoic acid Chemical compound C1=C(C(O)=O)C(OC(=O)C)=CC=C1C1=CC=C(F)C=C1 XKSAJZSJKURQRX-UHFFFAOYSA-N 0.000 description 1
- SYCHUQUJURZQMO-UHFFFAOYSA-N 4-hydroxy-2-methyl-1,1-dioxo-n-(1,3-thiazol-2-yl)-1$l^{6},2-benzothiazine-3-carboxamide Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=CS1 SYCHUQUJURZQMO-UHFFFAOYSA-N 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- WHPAGCJNPTUGGD-UHFFFAOYSA-N Croconazole Chemical compound ClC1=CC=CC(COC=2C(=CC=CC=2)C(=C)N2C=NC=C2)=C1 WHPAGCJNPTUGGD-UHFFFAOYSA-N 0.000 description 1
- 206010012504 Dermatophytosis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 101800001751 Melanocyte-stimulating hormone alpha Proteins 0.000 description 1
- KWKZCGMJGHHOKJ-ZKWNWVNESA-N Methyl Arachidonyl Fluorophosphonate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCCP(F)(=O)OC KWKZCGMJGHHOKJ-ZKWNWVNESA-N 0.000 description 1
- 241001460074 Microsporum distortum Species 0.000 description 1
- 206010028080 Mucocutaneous candidiasis Diseases 0.000 description 1
- 206010065764 Mucosal infection Diseases 0.000 description 1
- JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 description 1
- 208000010195 Onychomycosis Diseases 0.000 description 1
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 102000005782 Squalene Monooxygenase Human genes 0.000 description 1
- 108020003891 Squalene monooxygenase Proteins 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000222126 [Candida] glabrata Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 229960001671 azapropazone Drugs 0.000 description 1
- WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 1
- 229960000333 benzydamine Drugs 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 208000032343 candida glabrata infection Diseases 0.000 description 1
- JYIKNQVWKBUSNH-QWDBRQCVSA-N caspofungin Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)CC(C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCCC(C)CC(C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-QWDBRQCVSA-N 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960003749 ciclopirox Drugs 0.000 description 1
- SCKYRAXSEDYPSA-UHFFFAOYSA-N ciclopirox Chemical compound ON1C(=O)C=C(C)C=C1C1CCCCC1 SCKYRAXSEDYPSA-UHFFFAOYSA-N 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229960002042 croconazole Drugs 0.000 description 1
- 239000003260 cyclooxygenase 1 inhibitor Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- OEHFRZLKGRKFAS-UHFFFAOYSA-N droxicam Chemical compound C12=CC=CC=C2S(=O)(=O)N(C)C(C2=O)=C1OC(=O)N2C1=CC=CC=N1 OEHFRZLKGRKFAS-UHFFFAOYSA-N 0.000 description 1
- 229960001850 droxicam Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000008686 ergosterol biosynthesis Effects 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 229950007979 flufenisal Drugs 0.000 description 1
- 229950001284 fluprofen Drugs 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QFGMXJOBTNZHEL-UHFFFAOYSA-N isoxepac Chemical compound O1CC2=CC=CC=C2C(=O)C2=CC(CC(=O)O)=CC=C21 QFGMXJOBTNZHEL-UHFFFAOYSA-N 0.000 description 1
- 229950011455 isoxepac Drugs 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000003843 mucus production Effects 0.000 description 1
- 229960000916 niflumic acid Drugs 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000008756 pathogenetic mechanism Effects 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229960001589 posaconazole Drugs 0.000 description 1
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229960005429 sertaconazole Drugs 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229950005175 sudoxicam Drugs 0.000 description 1
- 229960002607 sulconazole Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 201000005882 tinea unguium Diseases 0.000 description 1
- 229960002905 tolfenamic acid Drugs 0.000 description 1
- YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- 229960004880 tolnaftate Drugs 0.000 description 1
- FUSNMLFNXJSCDI-UHFFFAOYSA-N tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 229960004740 voriconazole Drugs 0.000 description 1
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT8262006 | 2006-05-12 | ||
| PCT/AT2007/000227 WO2007131253A2 (de) | 2006-05-12 | 2007-05-10 | Verwendung von kombinationspräparaten, umfassend antimykotika |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009536926A true JP2009536926A (ja) | 2009-10-22 |
| JP2009536926A5 JP2009536926A5 (https=) | 2010-06-24 |
Family
ID=37903545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009508042A Pending JP2009536926A (ja) | 2006-05-12 | 2007-05-10 | 抗真菌剤を含む複合製剤の使用 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US8552042B2 (https=) |
| EP (2) | EP2018164B1 (https=) |
| JP (1) | JP2009536926A (https=) |
| CN (1) | CN101484162A (https=) |
| AU (1) | AU2007250502B2 (https=) |
| CA (1) | CA2651726C (https=) |
| CY (1) | CY1119094T1 (https=) |
| DK (1) | DK2018164T3 (https=) |
| ES (1) | ES2627268T3 (https=) |
| HR (1) | HRP20170793T1 (https=) |
| HU (1) | HUE033499T2 (https=) |
| LT (1) | LT2018164T (https=) |
| NO (2) | NO342103B1 (https=) |
| PL (1) | PL2018164T3 (https=) |
| PT (1) | PT2018164T (https=) |
| RS (1) | RS56044B1 (https=) |
| RU (1) | RU2008148977A (https=) |
| SI (1) | SI2018164T1 (https=) |
| WO (1) | WO2007131253A2 (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015522059A (ja) * | 2012-07-13 | 2015-08-03 | ルサッフル・エ・コンパニーＬｅｓａｆｆｒｅ Ｅｔ Ｃｏｍｐａｇｎｉｅ | 膣真菌症を予防及び／又は処置するためのサッカロマイセス・セレビシエ酵母 |
| JP2021503002A (ja) * | 2017-11-14 | 2021-02-04 | プロフェム・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＰｒｏＦｅｍ ＧｍｂＨ | 皮膚および粘膜感染症の局所治療用エマルション |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI23311A (sl) * | 2010-03-19 | 2011-09-30 | Kemijski inštitut | Farmacevtska kombinacija acetilsalicilne kisline in protiglivne substance za uničevanje ali inhibicijo rasti in replikacije gliv |
| CN102210649A (zh) * | 2010-04-09 | 2011-10-12 | 上海医药科技发展有限公司 | 一种两性霉素b乳膏及其制备方法 |
| CN103044408A (zh) * | 2013-01-21 | 2013-04-17 | 万礼 | 在治疗恶性肿瘤时应用的伊曲康唑或其盐及其组合物 |
| US8883747B1 (en) * | 2013-10-09 | 2014-11-11 | Craig W. Carver | Topical antifungal compositions and methods of use thereof |
| BR112017014295B1 (pt) | 2015-01-13 | 2023-04-25 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A | Composição farmacêutica. |
| CN104920360B (zh) * | 2015-06-18 | 2017-04-12 | 青岛农业大学 | 丁苯羟酸在制备用于防治由植物病原菌引起的植物病害的杀菌剂中的用途 |
| EP3482744A1 (de) | 2017-11-14 | 2019-05-15 | ProFem GmbH | Emulsionen zur topischen behandlung urogenitaler und dermaler infektionen |
| EP3482743A1 (de) | 2017-11-14 | 2019-05-15 | ProFem GmbH | Emulsionen zur behandlung von scheideninfektionen |
| FR3089788B1 (fr) * | 2018-12-17 | 2020-12-18 | Lesaffre & Cie | Souche de levure Saccharomyces cerevisiae pour le traitement et/ou la prévention de candidoses oropharyngées |
| US20250302821A1 (en) * | 2022-05-12 | 2025-10-02 | St. Jude Children's Research Hospital, Inc. | Synergistic antifungal composition and method |
| WO2024187210A1 (de) | 2023-03-15 | 2024-09-19 | Profem Gmbh | Kombinationsarzneimittel zur behandlung und reduktion der rückfallraten vaginaler mykosen |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09510185A (ja) * | 1993-12-23 | 1997-10-14 | ザ、プロクター、エンド、ギャンブル、カンパニー | 組織モイスチャライジング及び抗菌組成物 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6471823A (en) * | 1987-09-12 | 1989-03-16 | Rohto Pharma | Sustained remedy for vaginal candidiasis |
| US5087620A (en) * | 1990-05-17 | 1992-02-11 | Bristol-Myers Squibb Co. | Controlled dermal penetration enhancement using imidazoles |
| ES2079994B1 (es) * | 1992-10-07 | 1996-08-01 | Cusi Lab | Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica. |
| US6416779B1 (en) * | 1997-06-11 | 2002-07-09 | Umd, Inc. | Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections |
| US6159977A (en) | 1998-11-16 | 2000-12-12 | Astan, Inc. | Therapeutic anti-fungal nail preparation |
| WO2000048633A1 (en) | 1999-02-19 | 2000-08-24 | Ligocyte Pharmaceuticals, Inc. | Antibodies against hydrophobic proteins that are protective against candidiasis |
| EP1191939B1 (en) * | 1999-03-24 | 2007-10-17 | Zengen, Inc. | Antimicrobial amino acid sequences derived from alpha-melanocyte-stimulating hormone |
| GB0108082D0 (en) | 2001-03-30 | 2001-05-23 | Novartis Consumer Health Sa | Topical composition |
| US20030181384A1 (en) * | 2001-09-06 | 2003-09-25 | Podolsky Daniel K. | Methods and compositions for treating vaginal, cervical, and uterine epithelial lesions |
| US20040142910A1 (en) * | 2002-10-21 | 2004-07-22 | Aegis Biosciences Llc | Sulfonated styrene copolymers for medical uses |
| WO2004060283A2 (en) * | 2002-12-16 | 2004-07-22 | Nitromed, Inc. | Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use |
| JPWO2005000287A1 (ja) | 2003-06-25 | 2006-10-05 | 久光製薬株式会社 | 水虫治療用外用剤 |
| ES2237298B1 (es) | 2003-07-16 | 2006-11-01 | Italfarmaco, S.A. | Formulaciones mucoadhesivas semisolidas. |
| WO2005009342A2 (en) * | 2003-07-16 | 2005-02-03 | Pharmacia Corporation | Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith |
| TWI290051B (en) | 2004-05-28 | 2007-11-21 | Schering Corp | Particulate-stabilized injectable pharmaceutical compositions of Posaconazole |
-
2007
- 2007-05-10 EP EP07718439.8A patent/EP2018164B1/de active Active
- 2007-05-10 PL PL07718439T patent/PL2018164T3/pl unknown
- 2007-05-10 RU RU2008148977/15A patent/RU2008148977A/ru not_active Application Discontinuation
- 2007-05-10 SI SI200731935A patent/SI2018164T1/sl unknown
- 2007-05-10 RS RS20170559A patent/RS56044B1/sr unknown
- 2007-05-10 CN CNA200780025026XA patent/CN101484162A/zh active Pending
- 2007-05-10 DK DK07718439.8T patent/DK2018164T3/en active
- 2007-05-10 ES ES07718439.8T patent/ES2627268T3/es active Active
- 2007-05-10 HU HUE07718439A patent/HUE033499T2/en unknown
- 2007-05-10 CA CA2651726A patent/CA2651726C/en active Active
- 2007-05-10 EP EP17158393.3A patent/EP3192507B1/de active Active
- 2007-05-10 US US12/300,578 patent/US8552042B2/en active Active
- 2007-05-10 JP JP2009508042A patent/JP2009536926A/ja active Pending
- 2007-05-10 HR HRP20170793TT patent/HRP20170793T1/hr unknown
- 2007-05-10 AU AU2007250502A patent/AU2007250502B2/en active Active
- 2007-05-10 LT LTEP07718439.8T patent/LT2018164T/lt unknown
- 2007-05-10 WO PCT/AT2007/000227 patent/WO2007131253A2/de not_active Ceased
- 2007-05-10 PT PT77184398T patent/PT2018164T/pt unknown
-
2008
- 2008-12-11 NO NO20085181A patent/NO342103B1/no unknown
-
2013
- 2013-10-02 US US14/044,532 patent/US8815925B2/en active Active
-
2017
- 2017-05-30 CY CY20171100556T patent/CY1119094T1/el unknown
-
2018
- 2018-01-18 NO NO20180083A patent/NO345064B1/no unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09510185A (ja) * | 1993-12-23 | 1997-10-14 | ザ、プロクター、エンド、ギャンブル、カンパニー | 組織モイスチャライジング及び抗菌組成物 |
Non-Patent Citations (3)
| Title |
|---|
| JPN6012026672; ＡＬＥＭ，Ｍ．Ａ． ｅｔ ａｌ: 'Ｅｆｆｅｃｔｓ ｏｆ ａｓｐｉｒｉｎ ａｎｄ ｏｔｈｅｒ ｎｏｎｓｔｅｒｏｉｄａｌ ａｎｔｉ-ｉｎｆｌａｍｍａｔｏｒｙ ｄｒｕｇｓ ｏｎ ｂｉｏｆｉｌｍｓ ａｎｄ ｐｌａｎｋｔｏｎｉｃ ｃｅｌｌｓ ｏ' Ａｎｔｉｍｉｃｒｏｂｉａｌ Ａｇｅｎｔｓ ａｎｄ Ｃｈｅｍｏｔｈｅｒａｐｙ Ｖｏｌ．４８， Ｎｏ．１, 2004, ｐ．４１-４７ * |
| JPN6012026673; 衛生試験所報告 １０３, 1985, ｐ．１-５ * |
| JPN7012001960; ＹＵＣＥＳＯＹ，Ｍ． ｅｔ ａｌ: 'Ｉｎ-ｖｉｔｒｏ ｓｙｎｅｒｇｉｓｔｉｃ ｅｆｆｅｃｔ ｏｆ ｆｌｕｃｏｎａｚｏｌｅ ｗｉｔｈ ｎｏｎｓｔｅｒｏｉｄａｌ ａｎｔｉ-ｉｎｆｌａｍｍａｔｏｒｙ ａｇｅｎｔｓ ａｇａｉｎｓｔ Ｃａｎｄｉｄ' Ｊｏｕｒｎａｌ ｏｆ Ｃｈｅｍｏｔｈｅｒａｐｙ（Ｆｉｒｅｎｚｅ） Ｖｏｌ．１２， Ｎｏ．５, 2000, ｐ．３８５-３８９ * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015522059A (ja) * | 2012-07-13 | 2015-08-03 | ルサッフル・エ・コンパニーＬｅｓａｆｆｒｅ Ｅｔ Ｃｏｍｐａｇｎｉｅ | 膣真菌症を予防及び／又は処置するためのサッカロマイセス・セレビシエ酵母 |
| JP2021503002A (ja) * | 2017-11-14 | 2021-02-04 | プロフェム・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＰｒｏＦｅｍ ＧｍｂＨ | 皮膚および粘膜感染症の局所治療用エマルション |
| JP7378409B2 (ja) | 2017-11-14 | 2023-11-13 | プロフェム・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 皮膚および粘膜感染症の局所治療用エマルション |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3192507B1 (de) | 2020-07-08 |
| CA2651726A1 (en) | 2007-11-22 |
| RS56044B1 (sr) | 2017-09-29 |
| HUE033499T2 (en) | 2017-12-28 |
| SI2018164T1 (sl) | 2017-07-31 |
| US20090208558A1 (en) | 2009-08-20 |
| WO2007131253A2 (de) | 2007-11-22 |
| RU2008148977A (ru) | 2010-06-20 |
| AU2007250502B2 (en) | 2013-11-28 |
| AU2007250502A1 (en) | 2007-11-22 |
| DK2018164T3 (en) | 2017-06-12 |
| US8815925B2 (en) | 2014-08-26 |
| NO20085181L (no) | 2009-02-10 |
| PL2018164T3 (pl) | 2017-08-31 |
| CN101484162A (zh) | 2009-07-15 |
| CY1119094T1 (el) | 2018-01-10 |
| LT2018164T (lt) | 2017-07-10 |
| EP3192507A1 (de) | 2017-07-19 |
| ES2627268T3 (es) | 2017-07-27 |
| EP2018164A2 (de) | 2009-01-28 |
| NO20180083A1 (no) | 2009-02-10 |
| PT2018164T (pt) | 2017-06-12 |
| NO342103B1 (no) | 2018-03-26 |
| HRP20170793T1 (hr) | 2017-10-06 |
| NO345064B1 (no) | 2020-09-14 |
| EP2018164B1 (de) | 2017-03-01 |
| CA2651726C (en) | 2015-12-15 |
| WO2007131253A3 (de) | 2008-11-27 |
| US8552042B2 (en) | 2013-10-08 |
| US20140030312A1 (en) | 2014-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009536926A (ja) | 抗真菌剤を含む複合製剤の使用 | |
| US20030017207A1 (en) | Compositions and methods for treating vulvovaginitis and vaginosis | |
| JP2018502128A (ja) | 真菌感染を阻害するための組成物および方法 | |
| US20160199329A1 (en) | Broad spectrum pharmacological composition for treatmentof various infections and diseases and methodsof use | |
| ES2963980T3 (es) | Emulsiones para el tratamiento tópico de infecciones dérmicas y mucosas | |
| Rai et al. | Tinea versicolor–an epidemiology | |
| TYu et al. | Vulvovaginal candidiasis: modern look at the problem | |
| Tirri | Antimicrobial topical agents used in the vagina | |
| CN104244942A (zh) | 两性表面活性剂在预防和治疗阴道感染中的致病性阴道生物被膜中的应用 | |
| JP2023527358A (ja) | 肺線維症を処置する方法 | |
| AU2017261517B2 (en) | Use of combination preparations, comprising antimycotics | |
| Botter | Further experiences with miconazole nitrate, a broad‐spectrum antimycotic with antibacterial activity | |
| AU2013254945A1 (en) | Use of combination preparations, comprising antimycotics | |
| Boolaky et al. | Otomycosis-a review of current management trends | |
| CA3077447A1 (en) | Method to treat antimicrobial resistant candida | |
| OLTEAN | MANAGEMENT OF MUCOCUTANEOUS CANDIDIASIS | |
| JP2007518797A (ja) | 膣感染症の処置のための、フルコナゾール−チニダゾールの組み合わせ、ならびに、その組成物、調製プロセスおよび使用 | |
| Temiz et al. | Topical Antifungals | |
| US20240100004A9 (en) | Topical compositions and methods of formulating same | |
| Seid | Fungal infections | |
| AU2002309593A1 (en) | Composition comprising antifungal agents for treating vulvovaginitis and vaginosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100510 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100510 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120529 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20121030 |